I thought 43 was a steal. If 37 range comes into play will be definitely loading up. I like the 12 month outlook and personally believe $100m mcap is a minimum as clinical trials prove themselves out. Retail play with new H2 group will be interesting in Q2 2020.
Ann: Leading pharmaceutical executive to be appointed as Chairman, page-12
Add BOD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $4.256M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| BOD (ASX) Chart |
Day chart unavailable